First two-drug HIV treatment approved by FDA
The US Food and Drug Administration (FDA) has approved the first two-drug treatment regimen for the treatment of human immunodeficiency virus type 1 (HIV-1).
Current standard HIV treatments comprise three or more drugs but the newly approved treatment, Juluca, is made up of just two — dolutegravir (ViiV Healthcare) and rilpivirine (Janssen). Both drugs have been previously approved to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months with no history of treatment failure.
“Limiting the number of drugs in any HIV treatment regimen can help reduce toxicity for patients,” said Debra Birnkrant, director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research.
The efficacy and safety of the two-drug treatment was evaluated in two clinical trials comprising 1,024 eligible participants. Participants were randomly assigned to remain on their current treatment or switch to Juluca.
The results from the Juluca group were comparable to the current treatment group and show that the two-drug treatment was as effective in keeping the HIV virus suppressed.
Diarrhoea and headache were the most common side effects recorded during the study and more serious side effects included liver problems and depression.
The FDA advised that Juluca should not be given with other anti-HIV drugs and may interact with other commonly used medications.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203989
Recommended from Pharmaceutical Press
Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.£35.00Buy now
Remington Education: Drug Information & Literature Evaluation teaches students how to effectively and efficiently locate and analyze up-to-date drug information and literature.£27.00Buy now